Paul D. Nathan, MBBS, PhD, FRCP, discusses the 5-year analysis of the COMBI-d and COMBI-v trials, which look at the long-term effects of dabrafenib plus trametinib in patients with BRAF V600–mutant unresectable or metastatic melanoma.
Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the 5-year analysis of the COMBI-d and COMBI-v trials, which look at the long-term effects of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600—mutant unresectable or metastatic melanoma.
At the 5-year follow-up, the progression-free survival rate was 19% and the overall survival rate was 34%. There is a cohort of patients who do well on the combination long term, according to Nathan. Now, physicians must figure out how to identify who is going to respond well to the combination at the baseline. Physicians have corroborated some earlier data based on a multivariate analysis and a regression tree analysis, looking at baseline characteristics to identify who is likely to do well, according to Nathan.
Physicians found some markers that are associated with durability of response, including whether someone has a normal lactate dehydrogenase, fewer than 3 organ sites involved, and a good performance status. The most powerful marker of durability of response is whether somebody has a complete response (CR) to treatment. However, that is not a baseline marker; rather, it is a marker that is generated while a patient is on treatment. In the trial, 19% of patients had a CR to treatment. In the 5-year outcome for the patients who had a CR, 49% were progression free and 71% were alive at 5 years.